DEVELOPMENT AND CLINICAL MANUFACTURE AGREEMENTDevelopment and Clinical Manufacture Agreement • November 8th, 2013 • CymaBay Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledNovember 8th, 2013 Company Industry JurisdictionThis Development and Clinical Manufacture Agreement (the “Agreement”) is made and entered into as of 30 April 2012 (the “Effective Date”) by and between METABOLEX, Inc., a Delaware corporation with its principal place of business located at 3876 Bay Center Place, Hayward, California 94545 (“METABOLEX”) and SIEGFRIED AG, a Swiss Company, with its principal address place of business located at Untere Brühlstrasse 4, Zofingen CH4800 Switzerland (“SIEGFRIED”). METABOLEX and SIEGFRIED may be referred to herein individually as a “Party” or collectively as the “Parties”.
DEVELOPMENT AND CLINICAL MANUFACTURE AGREEMENTDevelopment and Clinical Manufacture Agreement • October 17th, 2013 • CymaBay Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledOctober 17th, 2013 Company Industry JurisdictionThis Development and Clinical Manufacture Agreement (the “Agreement”) is made and entered into as of 30 April 2012 (the “Effective Date”) by and between METABOLEX, Inc., a Delaware corporation with its principal place of business located at 3876 Bay Center Place, Hayward, California 94545 (“METABOLEX”) and SIEGFRIED AG, a Swiss Company, with its principal address place of business located at Untere Brühlstrasse 4, Zofingen CH4800 Switzerland (“SIEGFRIED”). METABOLEX and SIEGFRIED may be referred to herein individually as a “Party” or collectively as the “Parties”.
DEVELOPMENT AND CLINICAL MANUFACTURE AGREEMENTDevelopment and Clinical Manufacture Agreement • September 19th, 2013 • CymaBay Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledSeptember 19th, 2013 Company Industry JurisdictionThis Development and Clinical Manufacture Agreement (the “Agreement”) is made and entered into as of 30 April 2012 (the “Effective Date”) by and between METABOLEX, Inc., a Delaware corporation with its principal place of business located at 3876 Bay Center Place, Hayward, California 94545 (“METABOLEX”) and SIEGFRIED AG, a Swiss Company, with its principal address place of business located at Untere Brühlstrasse 4, Zofingen CH4800 Switzerland (“SIEGFRIED”). METABOLEX and SIEGFRIED may be referred to herein individually as a “Party” or collectively as the “Parties”.